Welcome to SynapCell's Booth here at Neuroscience 2022!
Glad to meet you in-person again, please send us a message to connect.
hello@synapcell.fr
SynapCell has been partnering with International pharmaceutical companies for almost 20 years and provides researchers with turnkey decision-making endpoints to secure their preclinical to clinical roadmap.
Our Cue® platform has pioneered the use of translational EEG biomarkers of CNS diseases for in vivo pharmacology testing in Epilepsy, Parkinson’s disease, Essential tremor, Schizophrenia, or neuropsychiatric disorders.
The pathophysiology of brain diseases is often the consequence of aberrant electrical signaling within neuronal networks. EEG enables to document these abnormalities and have them used as pathological biomarkers of CNS disorders. Its translational properties make it a predictive measure of brain dysfunction for a smooth translation to the clinic, and is used to monitor drug candidates’ pharmacodynamics with remarkable accuracy.
Beyond efficacy, EEG serves as a sentinel to pinpoint subtle neurophysiological changes in pathological context, such as the early signs of a neurodegenerative condition, or highlight links between a genotype and an EEG phenotype in genetic models of brain diseases, including rare, orphan disorders.
Brands: Cue® by SynapCell